In a post-hoc analysis comparing average stock prices from 120 to 60 days before results were announced to the average price for the subsequent 60 days, those reporting positive results saw a mean increase in share price of 9.4 percent.
FORBES: Why Pharma Stocks May Rise Before Trial Data Is Released